KRAS and pancreatic neoplasm: Anti-tumour efficacy of CAP has been shown in numerous studies using human cancer xenograft models of breast, colon, gastric, cervical, bladder ovarian and prostate cancer (see for review [7]) but only one study has been reported in a pancreas model [8] and this was in an atypical KRAS wild type pancreatic cancer cell xenograft.